Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This phase 2 study was designed to evaluate the activity of oral masitinib (AB1010)
administered at 2 dose levels during 24 weeks to patients with mild to moderate confirmed
Alzheimer's type disease.